R01CA249992

Oral Cavity Quantitative Histomorphometric Risk Classifier (OHBIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC) - Summary:

In 2018, nearly 34,000 adults in the US and over 275,000 worldwide were diagnosed with oral cavity squamous cell carcinoma (OC-SCC). In the US alone, over 6,600 died from the disease in 2018.

In addition to stage, perineural invasion, lymphovascular invasion, depth of invasion, and close or frankly positive resection margins are used to help stratify patients into low-, intermediate-, or high-risk categories.

Currently, all OC-SCC patients are treated primarily by surgical resection. Post-operative treatment depends on patient risk category. Low-risk patients receive surgery alone, and studies have shown the benefit of PORT (post-operative radiation therapy) in selected patients.

A retrospective analysis of 1467 patients with low-risk OC-SCC, where 740 (50.4%) received PORT, had improved overall survival compared to 727 patients treated with surgery alone.

Identifying these patients and better stratifying their risk of progression is critical. Meanwhile, patients with loco-regionally advanced (i.e., intermediate and high risk) disease are treated with PORT as standard. Select high-risk patients may be treated with concomitant chemoradiation or subsequent chemotherapy.

There is thus an urgent need to develop companion diagnostic tools to better define which patients will benefit from PORT, or, if intermediate or high risk, who will benefit from systemic therapy intensification.

Recently, our group has developed an OC-SCC histomorphometric-based image risk classifier (OHBIC) that uses computerized measurements of nuclear orientation, texture, shape, and architecture from digital images of H&E-stained tumor sections to identify patients who are likely to recur versus those who are not.

OHBIC was trained and validated on N=115 OC-SCC patients, and it had a 2 and 7-fold higher correlation with disease-specific survival compared to the 7th edition AJCC N- and T-stage (clinical variables used in patient prognosis).

In this NIH R01, we seek to further improve the prognostic and predictive accuracy of OHBIC by incorporating new classes of image features relating to stromal morphology, pattern of invasion at the tumor leading edge, density and patterns of tumor infiltrating lymphocytes, and tumor cell multi-nucleation, features now recognized as potential histopathological markers of prognostic relevance in OC-SCC.

Additionally, we seek to 1) validate OHBIC as prognostic of survival in clinically defined low-risk patients and identify those low-risk patients who would benefit from PORT and 2) validate OHBIC as not only prognostic of survival but also predictive of benefit from chemotherapeutic intensification for patients with loco-regionally advanced disease.

This partnership will leverage long-standing collaborations in (1) digital pathomics from the Madabhushi Group at Case Western Reserve, (2) surgical pathology and oncology expertise in oral cancer from Vanderbilt University, Cleveland Clinic, San Francisco VA, and Tata Memorial Centre, Mumbai to establish OHBIC as a tissue non-destructive and affordable precision medicine (APM) solution for OC-SCC patients.

Emory University

TO IMPROVE SCREENING AND EARLY DETECTION STRATEGIES AND TO DEVELOP ACCURATE DIAGNOSTIC TECHNIQUES AND METHODS FOR PREDICTING THE COURSE OF DISEASE IN CANCER PATIENTS. SCREENING AND EARLY DETECTION RESEARCH INCLUDES DEVELOPMENT OF STRATEGIES TO DECREASE CANCER MORTALITY BY FINDING TUMORS EARLY WHEN THEY ARE MORE AMENABLE TO TREATMENT. DIAGNOSIS RESEARCH FOCUSES ON METHODS TO DETERMINE THE PRESENCE OF A SPECIFIC TYPE OF CANCER, TO PREDICT ITS COURSE AND RESPONSE TO THERAPY, BOTH A PARTICULAR THERAPY OR A CLASS OF AGENTS, AND TO MONITOR THE EFFECT OF THE THERAPY AND THE APPEARANCE OF DISEASE RECURRENCE. THESE METHODS INCLUDE DIAGNOSTIC IMAGING AND DIRECT ANALYSES OF SPECIMENS FROM TUMOR OR OTHER TISSUES. SUPPORT IS ALSO PROVIDED FOR ESTABLISHING AND MAINTAINING RESOURCES OF HUMAN TISSUE TO FACILITATE RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.394 - Cancer Detection and Diagnosis Research

National Cancer Institute (NCI) [HHS - NIH]

Atlanta, Georgia 303221119 United States

Single Zip Code

Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional) (PAR-19-264)

Amendment Since initial award the End Date has been extended from 11/30/25 to 08/31/26 and the total obligations have increased 356% from $697,902 to $3,179,124.